Patient characteristics
| Cases . | 1 . | 2 . | 3 . | 4 . | 5 . | 6 . | 7 . |
|---|---|---|---|---|---|---|---|
| Age, y | 46 | 32 | 24 | 50 | 56 | 45 | 58 |
| Hepatomegaly (H) and/or splenomegaly (S) | None | None | None | None | None | S+++ | S+++ |
| Diagnosis date (BM) | 08/05/02 | 02/22/02 | 01/28/02 | 07/08/02 | 11/20/00 | 01/11/02 | 09/01 |
| Prior Rx | Prednisone | Prednisone, R-CHOP × 8 | Prednisone | Prednisone | Prednisone, IFN-α | None | HU, CsA, prednisone |
| Study date | 08/05/02 | 02/22/02 | 05/14/02 | 07/08/02 | 6/12/02 | 05/02/02 | 08/01/02 |
| Follow-up, wk | 10 | 33 | 21 | 14 | 17 | 23 | 10 |
| Disease | HES | HES | HES | HES | HES | Eos-CMD | Eos-CMD, PRCA |
| Imatinib treatment status, before/after | |||||||
| Hgb, g/dL | 15.5/14.6 | 12.2/15.1 | 10.5/12.9 | 13.7/14.7 | 15.1/14.1 | 7.7/12.5 | 8.1/9.0 |
| WBC, × 109/L | 15.8/10.2 | 17.8/7.5 | 42.2/13.1 | 10.1/7.2 | 14.7/17.6 | 14.3/4.0 | 21.1/19.6 |
| ANC, × 109/L | 6.0/6.7 | 4.3/3.5 | 5.5/NA | 5.1/2.7 | 5.7/6.7 | 7.2/NA | 13.9/12.7 |
| ALC, × 109/L | 1.9/2.8 | 3.0/1.6 | 3.4/NA | 2.1/2.2 | 4.9/6.0 | 1.3/NA | 2.7/NA |
| AMC, × 109/L | 0.3/0.7 | 0.5/0.6 | 0.4/NA | 0.3/0.8 | 0.6/0.7 | 0.6/NA | 0.8/NA |
| AEC, × 109/L | 7.6/0.1 | 10.0/1.8 | 32.5/8.5 | 2.5/1.5 | 3.2/4.2 | 2.2/0.04 | 2.7/2.2 |
| Platelet, × 109/L | 185/180 | 271/204 | 329/276 | 276/281 | 304/270 | 53/99 | 125/229 |
| Alkaline phosphatase, 98-251 U/L | 400/NA | 187/NA | 703/NA | 182/93 | 175/211 | 303/387 | 219/387 |
| IL-5, less than 7.8 pg/mL | 38.2/< 7.8 | 9.9/< 7.8 | 13.7/ND | < 7.8/ND | < 7.8/ND | 21.0/< 7.8 | ND |
| Cytogenetics | 46XY | 46XY | ND | 46XY | 46XY | 46XY | Trisomy 8 |
| T-cell clone | ND | − | − | ND | + | ND | ND |
| BM overall cellularity, % before/after | 50/ND | 30/ND | 80/ND | 60/ND | 50/ND | 95/40 | 70/ND |
| BM Eos, % before/after | ↑/ND | ↑/ND | 35/ND | 20/ND | 15/ND | 20/CR | ↑/ND |
| Cases . | 1 . | 2 . | 3 . | 4 . | 5 . | 6 . | 7 . |
|---|---|---|---|---|---|---|---|
| Age, y | 46 | 32 | 24 | 50 | 56 | 45 | 58 |
| Hepatomegaly (H) and/or splenomegaly (S) | None | None | None | None | None | S+++ | S+++ |
| Diagnosis date (BM) | 08/05/02 | 02/22/02 | 01/28/02 | 07/08/02 | 11/20/00 | 01/11/02 | 09/01 |
| Prior Rx | Prednisone | Prednisone, R-CHOP × 8 | Prednisone | Prednisone | Prednisone, IFN-α | None | HU, CsA, prednisone |
| Study date | 08/05/02 | 02/22/02 | 05/14/02 | 07/08/02 | 6/12/02 | 05/02/02 | 08/01/02 |
| Follow-up, wk | 10 | 33 | 21 | 14 | 17 | 23 | 10 |
| Disease | HES | HES | HES | HES | HES | Eos-CMD | Eos-CMD, PRCA |
| Imatinib treatment status, before/after | |||||||
| Hgb, g/dL | 15.5/14.6 | 12.2/15.1 | 10.5/12.9 | 13.7/14.7 | 15.1/14.1 | 7.7/12.5 | 8.1/9.0 |
| WBC, × 109/L | 15.8/10.2 | 17.8/7.5 | 42.2/13.1 | 10.1/7.2 | 14.7/17.6 | 14.3/4.0 | 21.1/19.6 |
| ANC, × 109/L | 6.0/6.7 | 4.3/3.5 | 5.5/NA | 5.1/2.7 | 5.7/6.7 | 7.2/NA | 13.9/12.7 |
| ALC, × 109/L | 1.9/2.8 | 3.0/1.6 | 3.4/NA | 2.1/2.2 | 4.9/6.0 | 1.3/NA | 2.7/NA |
| AMC, × 109/L | 0.3/0.7 | 0.5/0.6 | 0.4/NA | 0.3/0.8 | 0.6/0.7 | 0.6/NA | 0.8/NA |
| AEC, × 109/L | 7.6/0.1 | 10.0/1.8 | 32.5/8.5 | 2.5/1.5 | 3.2/4.2 | 2.2/0.04 | 2.7/2.2 |
| Platelet, × 109/L | 185/180 | 271/204 | 329/276 | 276/281 | 304/270 | 53/99 | 125/229 |
| Alkaline phosphatase, 98-251 U/L | 400/NA | 187/NA | 703/NA | 182/93 | 175/211 | 303/387 | 219/387 |
| IL-5, less than 7.8 pg/mL | 38.2/< 7.8 | 9.9/< 7.8 | 13.7/ND | < 7.8/ND | < 7.8/ND | 21.0/< 7.8 | ND |
| Cytogenetics | 46XY | 46XY | ND | 46XY | 46XY | 46XY | Trisomy 8 |
| T-cell clone | ND | − | − | ND | + | ND | ND |
| BM overall cellularity, % before/after | 50/ND | 30/ND | 80/ND | 60/ND | 50/ND | 95/40 | 70/ND |
| BM Eos, % before/after | ↑/ND | ↑/ND | 35/ND | 20/ND | 15/ND | 20/CR | ↑/ND |
BM indicates bone marrow; Rx, treatment; IFN-α, interferon-alpha; R-CHOP; rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone; HU, hydroxyurea; CsA, cyclosporine A; HES, hypereosinophilic syndrome; EosCMD, eosinophilia-associated chronic myeloid disorder; PRCA, pure red cell aplasia; Hgb, hemoglobin concentration; WBC, white blood cell count; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; AEC, absolute eosinophil count; IL-5, interleukin 5; Eos, eosinophil; −, absent; +, present; ↑, increased; ND, not done; and NA, not available.